AstraZeneca moving from Schleswig-Holstein to Hamburg

27 April 2022
Pharmaceutical giant to create more jobs

AstraZeneca is moving its German headquarters from Wedel to Hamburg-Bahrenfeld in late April. The relocation to the site of a former marzipan factory should put the company on a growth course following job cuts last year. Plans are being laid to grow the workforce substantially in the coming months, the company said.

New office, jobs and work concept

AstraZeneca intends to create around 90 new jobs in various fields and to establish an activity-based working concept and thus attract new talent. Alexandra Bishop, Managing Director of AstraZeneca Germany, remarked: "Working practices have evolved and our new environment offers the best in technology, flexible workspaces that can be adapted to different needs, and an office space that meets our sustainability requirements as a growing company." The more central location would make it easier to network with partners in Hamburg including the Life Science Nord and Gesundheitswirtschaft Hamburg (GWHH) clusters and the Health Innovation Port.

AstraZeneca's new offices

Boosting Hamburg as a centre of innovation

AstraZeneca Deutschland had growth of 25 per cent and generated total sales of around EUR 950 million in 2021. The company employs more than 900 people nationwide. Michael Westhagemann, Senator for Economics termed the healthcare sector a "catalyst of research, an economic factor and job engine for the Hanseatic city," which AstraZeneca continues to push ahead. Healthcare is a focal point of the senate's Regional Innovation Strategy (RIS) to drive the development of innovative and sustainable solutions for key parts of society and forward-looking sectors. Emphasis is on health, climate and energy, mobility, data science and digitalisation as well as material sciences and new materials.


Sources and further information


AstraZeneca GmbH is the German subsidiary of the British-Swedish pharmaceutical company AstraZeneca PLC. The global, science-driven biopharmaceutical company focuses on the discovery, development and commercialization of prescription medicines in oncology, rare diseases and biopharmaceuticals, including cardiovascular, renal and metabolic, and respiratory and immunology. Headquartered in Cambridge, Britain, The group operates in more than 100 countries and is headquartered in Cambridge, Britain. 


Similar articles

DESY opens centre for X-ray and Nano Science

Cutting-edge research now possible in Science City building - three research institutions involved

Hamburg's economy gradually recovering from pandemic

Figures for 2021 indicate increased gross domestic product

Hamburg's health care sector remains on growth course

Government releases latest figures - share of healthcare sector steadily increasing

EU funding 3D printing of medicine and implants at UKE

Scientists test 3D printing and AI
The Consent Management Platform ( we use could not be loaded. This can happen if AdBlockers incorrectly block this URL. Some features such as maps, proximity search or forms, cannot be used this way. To use these features, please deactivate your AdBlocker or allow access to *